This case was reported in a literature article and described the occurrence of uveitis in a 38-year-old female subject who received DTP (A or W not known) vaccine. On an unknown date, an unknown time after receiving DTP (A or W not known) vaccine, the subject developed uveitis. Serious criteria included GSK medically significant. The outcome of uveitis was unknown. The investigator considered that there was a reasonable possibility that the uveitis may have been caused by DTP (A or W not known) vaccine. Additional information was provided: This case was reported in a literature article and described the occurrence of vaccine-associated uveitis in a 38-year-old female who was vaccinated with unspecified diphtheria, pertussis and tetanus (DPT) (acellular or whole cell) vaccine (manufacturer unknown). This case has been mentioned in table 1 in the literature article. The patient was part of observational study conducted to collect data on cases of vaccine-associated uveitis reported from 1984 to 2014 to three spontaneous reporting databases on adverse drug events. In addition, a literature search was performed using the keywords of uveitis, iritis, iridocyclitis, or vitritis, in combination with vaccines, hepatitis A, hepatitis B, human papilloma virus vaccine (HPV), Bacillus Calmette-Guerin (BCG), Brucella, (DPT); herpes, influenza, measles, measles, mumps, and rubella (MMR), pneumococcal, smallpox, tetanus, typhoid, Heine Medin, varicella, yellow fever, and zoster vaccine. No information on patient's medical history or family history or concomitant medication or concurrent condition was provided. On an unspecified date, the patient received unspecified DPT (acellular or whole cell) vaccine (administration route and site unspecified; dosages unknown; batch number not provided). (Information on which dose of a particular vaccine was associated with uveitis was not available in the reporting systems.) On an unspecified date between 1984 and 2014, between 1 day and 6 years after vaccination with unspecified DPT (acellular or whole cell) vaccine, the patient developed uveitis. Treatment was unknown. The outcome for the event was unknown. The authors considered the event of uveitis associated to unspecified DPT (acellular or whole cell) vaccine. The authors concluded "While uveitis may be a rare adverse effect of vaccines, awareness of this potential reaction to vaccines is important, as is reporting such occurrences to adverse drug reaction registries. That hepatitis B vaccine accounted for a disproportionate number of cases certainly piques curiosity about contributing factors for uveitis in association with hepatitis B vaccine. In a similar vein, we are also left with the question of why a disproportionate number of cases of vaccine-associated uveitis occur in females (199 in females versus 77 in males in our data). Future studies of vaccine-associated uveitis could focus on active surveillance and rigorous clinical    [Due to memory limitations, the remainder of this text could not be compared.]  evaluation of patients presenting with uveitis temporally related to vaccination". This is 1 of the 14 valid cases reported in the same literature article. This article is not available for regulatory submission due to copyright restriction.